(Q28269931)

English

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks

scientific article

In more languages

Statements

scholarly article

0 references

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks (English)

0 references

phase III clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1

object named as

Paul E Sax

0 references

Anthony M. Mills

object named as

Anthony Mills

3

1 reference

ORCID Public Data File 2021

author name string

Edwin DeJesus

2

0 references

Andrew Zolopa

4

0 references

Calvin Cohen

5

0 references

David Wohl

6

0 references

Joel E Gallant

7

0 references

Hui C Liu

8

0 references

Lijie Zhong

9

0 references

Kitty Yale

10

0 references

Kirsten White

11

0 references

Brian P Kearney

12

0 references

Javier Szwarcberg

13

0 references

Erin Quirk

14

0 references

Andrew K Cheng

15

0 references

language of work or name

0 references

publication date

30 June 2012

0 references

0 references

379

0 references

9835

0 references

2439-48

0 references

Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960917-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960917-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960917-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960917-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960917-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Antiretroviral prescribing patterns in treatment-naïve patients in the United States.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960917-9

7 January 2021

based on heuristic

inferred from DOI database lookup

British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960917-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960917-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960917-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960917-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960917-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960917-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960917-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Prediction of creatinine clearance from serum creatinine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960917-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/tenofovir df in the initial treatment of HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960917-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, d

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960917-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960917-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Initial viral decay to assess the relative antiretroviral potency of protease inhibitor-sparing, nonnucleoside reverse transcriptase inhibitor-sparing, and nucleoside reverse transcriptase inhibitor-sparing regimens for first-line therapy of HIV inf

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960917-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical implications of fixed-dose coformulations of antiretrovirals on the outcome of HIV-1 therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960917-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Patient-reported outcomes in virologically suppressed, HIV-1-Infected subjects after switching to a simplified, single-tablet regimen of efavirenz, emtricitabine, and tenofovir DF.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960917-9

7 January 2021

based on heuristic

inferred from DOI database lookup

A single tablet regimen is associated with higher adherence and viral suppression than multiple tablet regimens in HIV+ homeless and marginally housed people

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960917-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Adherence to antiretroviral treatment and correlation with risk of hospitalization among commercially insured HIV patients in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960917-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(12)60917-9

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28269931&oldid=1577226235"